Viewing Study NCT06601335


Ignite Creation Date: 2025-12-24 @ 10:35 PM
Ignite Modification Date: 2026-02-22 @ 9:39 AM
Study NCT ID: NCT06601335
Status: RECRUITING
Last Update Posted: 2024-11-14
First Post: 2024-08-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Sponsor: Akeso
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module